All In Biotech

Drug Trial Radar · NCT07122401

Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism

A Multicenter, Randomized, Double-blind, Double-dummy, Phase III Study to Evaluate the Efficacy and Safety of MT1013 Versus Cinacalcet as Active Control in Secondary Hyperparathyroidism Patients on Maintenance Dialysis

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 424 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

424

Planned (sponsor's estimate)

Start

Sep 30, 2025

Primary completion

Nov 26, 2026

Study completion Nov 26, 2026

Sponsor

Sponsor type
Industry
First posted
Aug 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

MT1013 is a first-in-class dual-target agonist. This study is a multicenter, randomized, double-blind, double-dummy phase III clinical study being conducetd to evaluate the efficacy and safety of MT1013 compared with active control cinacalcet in secondary hyperparathyroidism patients on maintenance dialysis. Subjects will be 1:1 randomized to receive MT1013 or cinacalcet for 26 weeks. Evaluations of iPTH, Ca, P, BMD, and biomarkers will be done across the study period, to compare efficacy and safety of MT1013 to cinacalcet.

Conditions

  • Secondary Hyperparathyroidism, Chronic Kidney Disease

Interventions

  • MT1013Drug

    MT1013 + dummy cinacalcet

  • CinacalcetDrug

    Cinacalcet + dummy MT1013

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with > 50% reduction from baseline in mean intact parathyroid (iPTH)Time frame: EAP(Week 22-27)
  2. Percentage of participants with > 30% reduction from baseline in mean iPTHTime frame: EAP(Week 22-27)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.